Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib and Tislelizumab in Advanced Tumors with HRD
NCT04985721Phase 2Unknown
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Feb 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib in solid tumor, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Clinical Benefit Rate at 12 weeks. Status: unknown.
02
Drugs
pamiparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04985721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985721.